Cargando…
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344730/ https://www.ncbi.nlm.nih.gov/pubmed/37457131 http://dx.doi.org/10.20517/cdr.2023.13 |
_version_ | 1785072923685421056 |
---|---|
author | Yoon, Won-Hee DeFazio, Anna Kasherman, Lawrence |
author_facet | Yoon, Won-Hee DeFazio, Anna Kasherman, Lawrence |
author_sort | Yoon, Won-Hee |
collection | PubMed |
description | Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance. |
format | Online Article Text |
id | pubmed-10344730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | OAE Publishing Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103447302023-07-15 Immune checkpoint inhibitors in ovarian cancer: where do we go from here? Yoon, Won-Hee DeFazio, Anna Kasherman, Lawrence Cancer Drug Resist Review Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and despite advancements in therapeutics, most women unfortunately still succumb to their disease. Immunotherapies, in particular immune checkpoint inhibitors (ICI), have been therapeutically transformative in many tumour types, including gynaecological malignancies such as cervical and endometrial cancer. Unfortunately, these therapeutic successes have not been mirrored in ovarian cancer clinical studies. This review provides an overview of the ovarian tumour microenvironment (TME), particularly factors associated with survival, and explores current research into immunotherapeutic strategies in EOC, with an exploratory focus on novel therapeutics in navigating drug resistance. OAE Publishing Inc. 2023-06-14 /pmc/articles/PMC10344730/ /pubmed/37457131 http://dx.doi.org/10.20517/cdr.2023.13 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Yoon, Won-Hee DeFazio, Anna Kasherman, Lawrence Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title | Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title_full | Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title_fullStr | Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title_full_unstemmed | Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title_short | Immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
title_sort | immune checkpoint inhibitors in ovarian cancer: where do we go from here? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344730/ https://www.ncbi.nlm.nih.gov/pubmed/37457131 http://dx.doi.org/10.20517/cdr.2023.13 |
work_keys_str_mv | AT yoonwonhee immunecheckpointinhibitorsinovariancancerwheredowegofromhere AT defazioanna immunecheckpointinhibitorsinovariancancerwheredowegofromhere AT kashermanlawrence immunecheckpointinhibitorsinovariancancerwheredowegofromhere |